BACKGROUND: There are insufficient reports on the outcomes and local recurrence rates for gastric neoplasms treated using argon plasma coagulation (APC). The purpose of this study was to analyze the clinical outcomes in early gastric cancer or gastric adenoma patients following APC treatment. METHODS: Seventy-one patients were enrolled and all underwent APC at the Asan Medical Center between July 2007 and August 2011. Clinical and oncological outcomes were analyzed. RESULTS: The median follow-up period was 20 months (interquartile range 13-29 months). Among the 71 patients we evaluated, nonlifting after submucosal saline injection was found in 35 patients and 15 patients (21.2%) experienced local recurrence with a median period of 10 months (IQR 5-13 months). The rate of local recurrence was higher in the nonlifting group and the 40-W group than in the lifting group and the 60- or 80-W groups (31.4 vs. 11.1%, p = 0.045 and 31.7 vs. 6.7%, p = 0.017, respectively). Multivariate analysis showed that the power setting with the 40-W and nonlifting groups after submucosal injection was associated with local recurrence. CONCLUSIONS: APC therapy after submucosal saline injection using high power (60 or 80 W) appears to be an effective alternative in the management of gastric neoplasm.
BACKGROUND: There are insufficient reports on the outcomes and local recurrence rates for gastric neoplasms treated using argon plasma coagulation (APC). The purpose of this study was to analyze the clinical outcomes in early gastric cancer or gastric adenomapatients following APC treatment. METHODS: Seventy-one patients were enrolled and all underwent APC at the Asan Medical Center between July 2007 and August 2011. Clinical and oncological outcomes were analyzed. RESULTS: The median follow-up period was 20 months (interquartile range 13-29 months). Among the 71 patients we evaluated, nonlifting after submucosal saline injection was found in 35 patients and 15 patients (21.2%) experienced local recurrence with a median period of 10 months (IQR 5-13 months). The rate of local recurrence was higher in the nonlifting group and the 40-W group than in the lifting group and the 60- or 80-W groups (31.4 vs. 11.1%, p = 0.045 and 31.7 vs. 6.7%, p = 0.017, respectively). Multivariate analysis showed that the power setting with the 40-W and nonlifting groups after submucosal injection was associated with local recurrence. CONCLUSIONS: APC therapy after submucosal saline injection using high power (60 or 80 W) appears to be an effective alternative in the management of gastric neoplasm.
Authors: Ji Yong Ahn; Hwoon-Yong Jung; Kee Don Choi; Ji Young Choi; Mi-Young Kim; Jeong Hoon Lee; Kwi-Sook Choi; Do Hoon Kim; Ho June Song; Gin Hyug Lee; Jin-Ho Kim; Young Soo Park Journal: Gastrointest Endosc Date: 2011-07-13 Impact factor: 9.427
Authors: Chun Han Chau; Wing Tai Siu; Bonita Ka Bo Law; Chung Ngai Tang; Shek Yuen Kwok; Yiu Wing Luk; Wai Cheung Lao; Michael Ka Wah Li Journal: Gastrointest Endosc Date: 2003-04 Impact factor: 9.427
Authors: T Sagawa; T Takayama; T Oku; T Hayashi; H Ota; T Okamoto; H Muramatsu; S Katsuki; Y Sato; J Kato; Y Niitsu Journal: Gut Date: 2003-03 Impact factor: 23.059